Collaborative Advancement of Recovery Excellence
Translating science to service, powered by Gloo
A longer duration of treatment with the injectable formulation of buprenorphine for opioid use disorder was associated with more favorable abstinence outcomes in a newly published study.
Sexual minority women appear to be at greater risk of substance use-related problems than heterosexual women, but major gaps remain in research, a review suggests.
Nineteen projects to improve access to treatment have received funding in a Foundation for Opioid Response Efforts round that attracted nearly 450 proposals.
The most comprehensive review yet of 12-Step based approaches to treating alcohol use disorder shows major benefits from 12-Step Facilitation.
Gloo and the Psychiatry and Behavioral Health Learning Network have announced a partnership to create a virtual center of excellence aimed at improving patient outcomes among mental health treatment and addiction recovery providers.
Even among treatment centers that espouse an abstinence approach, there is evidence of treatment's benefits in reducing harm from substance use, comprehensive outcome data from Vista Research Group suggest.
A cohort study has reported that a group receiving the longest duration of buprenorphine treatment had fewer hospitalizations and filled opioid prescriptions post-treatment.
Reports from poison control centers illustrate the medical risks associated with prescription amphetamine misuse, with administration by injection generally associated with the worst outcomes.
Stigma doesn't immediately disappear when innovative efforts to engage individuals with opioid use disorders are launched, say presenters at the Rx Drug Abuse & Heroin Summit.